Moderna’s market value has fallen by more than 90% — $185 billion, or a full Sony — from its 2021 peak to around $10 billion ...
A shot analysts projected as a multibillion-dollar seller produced results “well below” the company’s expectations, ...
Moderna is halting development of an mRNA vaccine for congenital cytomegalovirus after its candidate failed to protect women ...
"Now we are an oncology company," Moderna CEO Stéphane Bancel told Insider.
Stocktwits on MSN
Moderna Stock Slides After-Hours On CMV Vaccine Failure In Phase 3 Trial — Retail Traders Warn Of ‘Endless’ Cash Burn
Moderna said its cytomegalovirus (CMV) vaccine, mRNA-1647, failed to prevent infection in women of childbearing age in a ...
GlobalData on MSN
Moderna scraps mRNA vaccine in congenital CMV on Phase III failure
While development has been scrapped in CMV, a Phase II trial investigating the candidate in bone marrow transplant patients ...
Has BridgeBio's business model worked? How are executives at Moderna dealing with the company's slump? Find out on the new episode of "The Readout LOUD." ...
A key question for investors going forward will be whether Moderna's other latent virus vaccines for Epstein-Barr and ...
Dec 2 (Reuters) - Moderna Inc's (MRNA.O), opens new tab COVID-19 vaccine could be approved for emergency use within 24 to 72 hours after the U.S. health regulator's advisory committee meeting, Chief ...
Moderna is working on a stronger tool to fight the COVID-19 pandemic. However, officials say it will take time. The drugmaker says research is underway toward a one-dose, yearly booster to battle the ...
Dec 4 (Reuters) - Moderna Inc (MRNA.O), opens new tab will be able to produce 500 million doses of its COVID-19 vaccine in 2021, Chief Executive Officer Stéphane Bancel said on Friday. The company has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback